Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.48 |
| ▸ | DHODH | Q02127 | 7/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | GALR1 | P47211 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537652 | 0.89 | PTGS2 (0.54) | PTGS2DHODHPTGS1 | |
| SCHEMBL6718701 | 0.88 | PTGS2 (0.48) | PTGS2DHODHPTGS1GALR1PTGES2 | |
| SCHEMBL6729410 | 0.84 | PTGS2 (0.52) | PTGS2PTGS1PIM1PIM2 | |
| SCHEMBL7156049 | 0.82 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL6729354 | 0.81 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL6730144 | 0.81 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL6725499 | 0.81 | PTGS2 (0.46) | PTGS2DHODHPTGS1PIM1PIM2 | |
| SCHEMBL7046074 | 0.81 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL7048545 | 0.81 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL6729701 | 0.81 | DHODH (0.46) | PTGS2DHODHPTGS1GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885DHODH 2109/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.